On 2026年4月19日, the U.S. Food and Drug Administration (FDA) officially implemented the Import Digital Compliance Guidance for Medical Devices and Health-Related Products, requiring all overseas suppliers exporting medical devices and health-related products to the United States to establish a standalone, verifiable 'Product Compliance Statement' page on their B2B official websites, with bilingual dynamic loading support for English and the target market language (such as Spanish, Portuguese). This requirement directly affects segments such as medical devices, in vitro diagnostic reagents, and home health equipment that rely on China's supply chain for overseas expansion, because it will serve as a mandatory verification item in FDA import pre-screening. Failure to comply may lead to customs clearance delays or escalated sampling inspections, thereby impacting the market-entry efficiency and trust mechanism of the entire cross-border supply chain.

Event Overview

The U.S. FDA officially enforced the Import Digital Compliance Guidance for Medical Devices and Health-Related Products on 2026年4月19日. According to publicly available information, the guidance explicitly requires that: all official websites of overseas suppliers must include a standalone, non-redirectable 'Product Compliance Statement' page; the page must be transmitted via the HTTPS protocol and embed a timestamped digital signature to enable audit traceability; the content must support dynamic loading in English + at least one target market language (such as Spanish, Portuguese); and the page will be incorporated into the FDA import pre-screening system (ABI/Predetermined Entry Review) automated verification workflow as a key digital credential for assessing supplier qualification credibility.

Which Segments Will Be Affected

Direct Trading Companies

For foreign trade companies that directly sign sales contracts with U.S. customers, issue commercial invoices, and arrange exports, their official websites are the 'supplier official websites' recognized by the FDA. If they fail to deploy the required compliance statement page, related orders may trigger manual review or be flagged as high-risk during the FDA pre-screening stage, directly affecting document release timing and customer contract renewal evaluations.

Processing and Manufacturing Enterprises

As OEM/ODM manufacturers, although they may not export directly, they are often required by overseas brand owners to disclose upstream manufacturer information and compliance status on their websites. By tying website compliance to product market access, the FDA effectively means downstream brand owners may list 'whether a verifiable compliance statement page is in place' as a hard technical requirement for qualified supplier onboarding, forcing manufacturers to independently build and maintain such a page.

Channel Distribution Enterprises

These include U.S.-based distributors, importers (US Agent), and operators of self-owned brands on e-commerce platforms. Their upstream supply often depends on Chinese factories, and the new FDA rule makes 'supplier website compliance status' a key evidentiary node in their own import responsibility chain. If the partner factory's official website does not meet the standard, distribution companies may face FDA inquiries, import record anomalies, or requests to provide additional due diligence materials.

Supply Chain Service Enterprises

Service providers offering FDA registration agency services, regulatory consulting, and digital compliance technology deployment are shifting their business focus from single registration filings to supporting clients in building sustainable digital compliance infrastructure. The new rule sets clear technical requirements for HTTPS encryption, timestamp signatures, and multilingual dynamic loading, making service providers with cross-disciplinary capabilities in Web development and GxP data governance more practically valuable.

Key Points for Relevant Companies or Practitioners to Watch and How to Respond Now

Monitor Follow-up Implementation Rules and Frequently Asked Questions (FAQ) Released by the FDA

At present, the guidance only clarifies principle-level requirements and has not yet released page structure templates, signature algorithm standards, language coverage lists, or explanations of exemption scenarios. Companies should continue to track updates on the FDA official website, with particular attention to supporting technical guidelines that may be issued in 2026年 Q2.

Distinguish Between the 'Official Website Entity' and the 'Actual Exporting Entity' to Clarify Responsibility Allocation

If there are situations involving multi-brand groups or multi-entity operations (for example, the factory is registered under Company A, while exports are declared through Company B), it is necessary to confirm which entity's official website the FDA uses as the verification target. What deserves closer attention at present is whether the FDA will accept technical solutions such as 'embedding sub-brand compliance pages into the main official website' or 'pointing via DNS to the same page,' rather than simply requiring each registration number to correspond to an independent domain name.

Prioritize Language Adaptation for Core Product Categories and Main Markets

Spanish and Portuguese are explicitly mentioned, but they are not the only possible combination. Companies should align with the distribution of their export destinations (such as Mexico, Brazil, Spain) and prioritize deployment of corresponding language versions, avoiding blind coverage of all minor languages that would create redundant maintenance burdens. The dynamic loading mechanism must ensure that after language switching, the timestamp signature and page content remain fully bound together.

Simultaneously Review Existing Official Website Security Protocols and Content Management Processes

HTTPS is a mandatory prerequisite, and timestamp signatures must also be supported——this means static HTML pages cannot meet the requirement. Companies need to assess whether their current CMS system supports API-level signature invocation, or whether a lightweight compliance module needs to be introduced. At the same time, updates to compliance statement content must be incorporated into the change control process to ensure every revision can be traced back to the responsible person and point in time.

Editorial Viewpoint / Industry Observation

From an industry perspective, this new rule is better understood as a key step in the FDA's push to digitize import supervision, rather than an isolated tightening of compliance requirements. It consolidates qualification documents that were previously scattered across paper files, email exchanges, and third-party audits into the supplier's own digital interface. In essence, it brings the 'enterprise digital infrastructure capability' into the regulatory evaluation dimension. Analysis suggests that in the short term, this move will intensify technical adaptation pressure on small and medium-sized export enterprises, but in the medium to long term it may accelerate the standardization of compliance infrastructure across the industry. What is more worth watching now is whether this mechanism will be extended to other major market regulatory systems such as the EU MDR and Health Canada, forming an early signal of a trend toward cross-regional mutual recognition of digital compliance.

Conclusion

This new FDA rule marks that the compliance focus for exports of medical devices and other health-related products is shifting from 'document conformity' to 'system verifiability.' Its industry significance lies not in adding a new certification, but in transforming the official website itself into a compliant asset that is auditable, interoperable, and traceable. At present, it is more appropriate to view this as a forward-looking test of digital governance capability. Companies do not need to overreact, but they should incorporate it as one of the key indicators in their 2026年 Q2 supply chain resilience assessment.

Information Source Note

Main source: Import Guidance for Medical Devices and Health-Related Products (Digital Compliance Framework) published on the official website of the U.S. FDA, with an effective date of 2026年4月19日. Items requiring continued observation: whether the FDA will issue supplementary explanations on multilingual scope, signature technical standards, transition period arrangements, etc.